Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA White Oak Construction Nears Completion, But Some Plans On Hold

This article was originally published in The Tan Sheet

Executive Summary

The biodefense complex would remain on schedule for fiscal 2014 completion, but communications and logistical buildings included in the master plan would be on hold. FDA tells Congress the sprawling campus must receive necessary operational funds as more employees move there.

You may also be interested in...

Biosimilars, Generic Programs Leave Little Room For Other New FDA Drug Initiatives In FY ‘13

Proposed and existing user fees would fund 44% of the $4.5 billion FDA FY 2013 spending plan. User fees are projected at $20 million for biosimilars and $229 million for generic drugs.

FDA To Spend PDUFA Reserves To Fund Safety Officers, Personnel Moves

Agency will spend more than 78% of $150.6 million fund by the end of FY 2012 to move CBER to White Oak and pay for new drug safety personnel.

President's Budget Proposal Points To Expanding FDA User Fees

President Obama's fiscal 2012 budget request concurs with FDA in recommending that Congress expand the type of user fees that industry pays for food safety enforcement reform.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts